Liver cancer international最新文献

{"title":"Issue Information","authors":"","doi":"10.1002/lci2.46","DOIUrl":"https://doi.org/10.1002/lci2.46","url":null,"abstract":"","PeriodicalId":93331,"journal":{"name":"Liver cancer international","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43200111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Following Article belonging to this SPECIAL ISSUE has been Published in a previous issue of “Volume 2, Issue 3”","authors":"","doi":"10.1002/lci2.65","DOIUrl":"https://doi.org/10.1002/lci2.65","url":null,"abstract":"","PeriodicalId":93331,"journal":{"name":"Liver cancer international","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49230188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Percutaneous treatments of hepatocellular carcinoma: Improving efficacy, applicability and extending ablation criteria","authors":"E. Gigante, O. Sutter, P. Nahon, O. Seror, J. Nault","doi":"10.1002/lci2.35","DOIUrl":"https://doi.org/10.1002/lci2.35","url":null,"abstract":"The main curative treatments of early hepatocellular carcinoma (HCC) are liver resection, liver transplantation and percutaneous ablation. Monopolar radiofrequency ablation (RFA) was the most widely used percutaneous treatment but has limitations in terms of applicability and efficacy. These limitations could be responsible for downgrading the treatment of early HCC not amenable to usual monopolar RFA, transplantation or resection and to a shift to palliative treatment. However, improvement in ablation techniques during the last 10 years including the development of microwave ablation, multibipolar RFA, irreversible electroporation but also new technical tricks for ablation allowed to optimize the efficacy and promote the wide application of percutaneous treatments in patients with early HCC. It helped also to explore the ability of percutaneous ablation to treat HCC outside current guidelines in order to ablate more lesions of larger sizes. In this review, we aim to describe how the improvement of ablation methods helps to maximize the number of patients treated for early HCC and to discuss if we could extend the usual ablation criteria in order to allocate more patients in a curative setting.","PeriodicalId":93331,"journal":{"name":"Liver cancer international","volume":"3 1","pages":"37 - 46"},"PeriodicalIF":0.0,"publicationDate":"2022-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42533759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment allocation in patients with hepatocellular carcinoma: Need for a paradigm shift?","authors":"A. Vitale, M. Finotti, F. Trevisani, F. Farinati, E. Giannini","doi":"10.1002/lci2.42","DOIUrl":"https://doi.org/10.1002/lci2.42","url":null,"abstract":"Treatment allocation of patients with hepatocellular carcinoma (HCC) is an extremely complex process as this tumour usually arises in patients with liver cirrhosis, that may be complicated by features of portal hypertension and liver failure, and patients often present additional comorbidities, thus making the therapeutic decision process even more challenging.1 The complexity of this scenario has further increased in the last years due to a dramatic change in the treatment paradigm of HCC patients as well as in the landscape of patients developing this tumour.2,3 These changes mainly concerned systemic and surgical therapies of HCC but also the treatment of unresectable advanced tumours due to the current availability of three lines of systemic therapy with tyrosine kinase inhibitors and the recent advent of a frontline therapy more effective than sorafenib (ie, atezolizumab plus bevacizumab) that are the available novel standard of care as it is European Medicines Agency and Food and Drug Administration approved them for unresectable HCC.4,5 These advancements are expanding the reach of systemic therapy beyond the conventional limit of the advanced stage of the disease and, likely, such therapies will represent a valid therapeutic option together, or as an alternative, to locoregional therapies in all patients with unresectable HCC independently of tumour stage. On the contrary, the rising spread of miniinvasive approaches has radically improved the surgical treatment of HCC. The miniinvasive approach, in fact, has become a wellestablished positive prognostic factor in patients undergoing liver resection for HCC.6 The optimal candidacy to liver resection, in fact, now depends on a multiparametric evaluation that includes residual liver function, grade of portal hypertension, the volume of the remaining liver parenchyma and the possibility to apply a miniinvasive approach.7 Based on this new concept of resectability,8 liver resection should not be confined to specific subpopulations (or substages) based on the absence of a single adverse prognostic factor (ie, clinically relevant portal hypertension, increased serum bilirubin, multinodular pattern or vascular invasion). Lastly, the boundaries for the selection of patients for liver transplantation have widened due to the application of the transplant benefit concept and to the results of wellconducted, prospective studies that have demonstrated the effectiveness of downstaging strategies, thus increasing the candidacy to this curative procedure. Thus, on the basis of local organ resources, availability of alternative therapies, and waiting list competition issues, the indication to liver transplantation for HCC can include patients in almost all stages of liver disease (from very early to terminal stage HCC). These recent, relevant advances in the treatment, both systemic and surgical, of HCC patients, have made even more evident the limitations of a ‘stage hierarchy approach’ rigidly linking ea","PeriodicalId":93331,"journal":{"name":"Liver cancer international","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47212601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current development and future perspective of IDH1 inhibitors in cholangiocarcinoma","authors":"J. Adeva","doi":"10.1002/lci2.43","DOIUrl":"https://doi.org/10.1002/lci2.43","url":null,"abstract":"Biliary tract cancer (BTC) represents a major public health problem due to its increasing rates of incidence and mortality, especially the intrahepatic cholangiocarcinoma (IHCCA) subtype. First line palliative systemic treatment with cisplatin and gemcitabine has been the unique level IA evidence option until last few years when a deeper understanding of its molecular landscape has unveiled CCA as a very rich targetable disease. This has revolutionised the patient's scenario and has brought new targeted therapies guided by molecular aberrations. Isocitrate dehydrogenase (IDH)1 mutations are the most prevalent targetable alteration in CCA (13% of IHCCA). Ivosidenib has been very recently approved by FDA for IDH1 mutated CCA patients based on a randomised clinical trial (ClarIDHy).","PeriodicalId":93331,"journal":{"name":"Liver cancer international","volume":"3 1","pages":"17 - 31"},"PeriodicalIF":0.0,"publicationDate":"2021-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43410346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Latest advances in cholangiocarcinoma","authors":"A. Lamarca","doi":"10.1002/lci2.44","DOIUrl":"https://doi.org/10.1002/lci2.44","url":null,"abstract":"","PeriodicalId":93331,"journal":{"name":"Liver cancer international","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49191081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endoscopic considerations for the management of cholangiocarcinoma","authors":"Joe Geraghty","doi":"10.1002/lci2.40","DOIUrl":"10.1002/lci2.40","url":null,"abstract":"<p>Cholangiocarcinoma (CCA) is a rare malignancy of the biliary tract. The goals of endoscopy in CCA are to (a) provide an accurate diagnosis (tissue acquisition) and staging of disease and (b) relieve biliary obstruction and associated symptoms such as pruritis (stent placement). This then facilitates optimal treatment to occur; be this surgical resection, uninterrupted chemotherapy or improvement in symptoms. Endoscopy can involve endoscopic retrograde cholangiopancreatography with or without cholangioscopy, or endoscopic ultrasound with fine-needle aspiration to support these goals of making surgery safer and chemotherapy possible while avoiding endoscopy compilations such as pancreatitis and sepsis.</p>","PeriodicalId":93331,"journal":{"name":"Liver cancer international","volume":"2 3","pages":"96-101"},"PeriodicalIF":0.0,"publicationDate":"2021-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/lci2.40","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42205867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatotoxicity of systemic therapies for unresectable hepatocellular carcinoma","authors":"Ciro Celsa,&nbsp;Paolo Giuffrida,&nbsp;Carmelo Marco Giacchetto,&nbsp;Caterina Stornello,&nbsp;Gabriele Rancatore,&nbsp;Mauro Grova,&nbsp;Maria Rita Ricciardi,&nbsp;Sergio Rizzo,&nbsp;Calogero Cammà,&nbsp;Giuseppe Cabibbo","doi":"10.1002/lci2.38","DOIUrl":"10.1002/lci2.38","url":null,"abstract":"<p>The number of effective systemic therapies for the treatment of unresectable hepatocellular carcinoma (uHCC) is rapidly increasing and the advent of immunotherapy changed the treatment paradigm for these patients, leading to a significant improvement in survival outcomes. While sorafenib, a tyrosine-kinase inhibitor monotherapy, remained the only effective treatment for almost a decade, the combination of atezolizumab, an immune checkpoint inhibitor (ICI) targeting programmed death-ligand 1, plus bevacizumab, an antiangiogenic agent targeting vascular endothelial growth factor, now represents the new standard of care for patients with uHCC. Moreover, several further clinical trials are ongoing to evaluate novel combinations between ICIs with other drugs, belonging to the same class or to other classes. As HCC occurs in most cases in the setting of cirrhosis, the evaluation of the risk/benefit ratio of systemic treatments represents a critical point. The underlying liver disease significantly influences the safety and the effectiveness of current and future systemic treatments for uHCC. For this reason, the hepatotoxicity profile and impact on liver function of these molecules should be carefully assessed in both clinical trials and in the real-world setting. Here, we review hepatotoxicity data on systemic treatments for uHCC and offer suggestions on monitoring and managing liver-related adverse events occurring during the treatment.</p>","PeriodicalId":93331,"journal":{"name":"Liver cancer international","volume":"2 3","pages":"82-95"},"PeriodicalIF":0.0,"publicationDate":"2021-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/lci2.38","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47458286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multicentre external validation of the GES score for predicting HCC risk in Japanese HCV patients who achieved SVR following DAAs","authors":"Kazumichi Abe,&nbsp;Masashi Fujita,&nbsp;Manabu Hayashi,&nbsp;Atsushi Takahashi,&nbsp;Hiromasa Ohira,&nbsp;Nabiel Mikhail,&nbsp;Reham Soliman,&nbsp;Gamal Shiha","doi":"10.1002/lci2.41","DOIUrl":"10.1002/lci2.41","url":null,"abstract":"<p>A simple score combining clinical and biochemical parameters (general evaluation score (GES)) has shown value in predicting hepatocellular carcinoma (HCC) risk after hepatitis C virus (HCV) eradication in Egyptian patients with HCV genotype 4. We aimed to apply the GES to predict HCC risk in Japanese HCV patients who achieved sustained virological response (SVR) following direct-acting antivirals (DAAs). This multicentre retrospective cohort study included 187 HCV patients without a history of HCC treatment who achieved SVR. The GES was calculated using pre- and post-treatment data. The median age of the patients was 66 years; 49% were male, 89% had cirrhosis and 69% had HCV genotype 1. During the mean 36-month follow-up, 19 (10.2%) developed HCC. Regarding the pretreatment scores, 75 (40.1%), 58 (31.0%) and 54 (28.9%) patients had low-, intermediate- and high-risk scores, respectively. The 4-year cumulative incidence (CumI) was 1.64% in the low-risk group, 2.82% in the intermediate-risk group and 6.88% in the high-risk group (log-rank <i>P</i> = .029). In patients with cirrhosis, 60 (36.1%), 57 (34.3%) and 49 (29.5%) had low-, intermediate- and high-risk scores respectively. The 4-year CumI was 0.98% in the low-risk group, 2.86% in the intermediate-risk group and 6.67% in the high-risk group (log-rank <i>P</i> = .02). The GES calculated with pretreatment data was more useful than that calculated with post-treatment data (Harrell's C statistic: 0.670 vs 0.587). This tool incorporates changes over time to estimate variations in HCC risk and could help identify low-risk patients for whom HCC surveillance can be discontinued.</p>","PeriodicalId":93331,"journal":{"name":"Liver cancer international","volume":"2 3","pages":"102-109"},"PeriodicalIF":0.0,"publicationDate":"2021-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/lci2.41","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47816677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unmet needs in basic and translational research in Cholangiocarcinoma","authors":"M. Cadamuro, R. Macías, A. Strain, M. Strazzabosco, P. Simioni, J. Marin, L. Fabris","doi":"10.1002/lci2.39","DOIUrl":"https://doi.org/10.1002/lci2.39","url":null,"abstract":"Despite the impact of cutting‐edge technologies in providing deep molecular phenotyping of many tumours, management of cholangiocarcinoma (CCA), a rare and insufficiently studied cancer with marked heterogeneity (including intrahepatic and extrahepatic variants), has remained limited and it has poor prognosis. Renewed interest in this enigmatic disease has been fostered in the last decade. Here, we will give an overview of the most important gaps in knowledge of the basic and translational research of CCA that must be prioritized to improve the CCA management in the future.","PeriodicalId":93331,"journal":{"name":"Liver cancer international","volume":"3 1","pages":"16 - 5"},"PeriodicalIF":0.0,"publicationDate":"2021-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42920941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}